Metabolism and disposition of dasatinib after oral administration to humans. - Wikidata - wikimedia - TriplyDB

Metabolism and disposition of dasatinib after oral administration to humans.

Metabolism and disposition of dasatinib after oral administration to humans.

http://www.wikidata.org/entity/Q46638270

about

Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects Exploring the utility of high-resolution MS with post-acquisition data mining for simultaneous exogenous and endogenous metabolite profiling.New dosing schedules of dasatinib for CML and adverse event management Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases.Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Metabolism considerations for kinase inhibitors in cancer treatment Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.Src Dependent Pancreatic Acinar Injury Can Be Initiated Independent of an Increase in Cytosolic Calcium.Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.DMSO-enhanced MALDI MS imaging with normalization against a deuterated standard for relative quantification of dasatinib in serial mouse pharmacology studies.Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.Src inhibitors in suppression of papillary thyroid carcinoma growth.Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.Pharmacokinetic considerations for new targeted therapies.Acute renal failure under dasatinib therapy.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.From known knowns to known unknowns: predicting in vivo drug metabolites.The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Reflecting on a decade of metabolite screening and monitoring.Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes.Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.

P2860

Q23923997-31633567-0F8A-4FBD-BBC6-FE6E3B67153D Q28730433-725D7B5C-A005-42DB-AC1A-E6DA48B95107 Q30636316-7F845408-BAB1-46D3-9A1B-319867B8221D Q33383407-9AA8EE72-CB37-4128-9307-EDC8595C4CF9 Q33383664-6368F5A4-7DE4-4F7B-A3F5-A1C195746678 Q33383954-DE93B3CA-CB8C-40E8-859E-AC66EDCAC1F6 Q33384361-8A570E71-7BBA-4CFF-A15C-75F399B8B2BC Q33397085-3EBFE44B-CA31-4B67-AA69-26C1893F2639 Q33811937-8FE9953E-DF23-4628-936A-55A3EE44AC63 Q34100838-25671861-E628-492E-ADCC-00DFF3C4CED2 Q34134390-C1AEC4C3-9B77-4B9D-A2EF-EEBF4B702A82 Q34578584-4B8A07E6-7EA4-4AEE-AB00-311FC2326C59 Q34606869-2150C093-FF79-4291-9823-A6DA72148D32 Q34743481-4861BC26-786C-460B-B058-C9149C7A36E4 Q34793419-8E8550C8-1C59-4928-917F-89E4EF533397 Q34926036-52374009-CDFF-427F-AE91-8B84A89376C2 Q35016405-01CA6F3C-D68B-48A7-8A07-09943007B874 Q35050740-EDBB2268-6DA2-49A9-A3D0-CEDC8871E385 Q35457965-288DC9AA-7A97-4E55-9011-AF133A66601E Q36010168-B04F7F52-37F7-474A-A7D0-FC9A93BE5414 Q36624496-A32772C3-6772-4999-9B6C-679BADB8E487 Q36657755-EA167342-C962-47B6-A4AE-84417913E3A4 Q36918220-2C641D42-6F12-4382-9A0C-5CDE1D08BD82 Q37028648-21E5F76A-1EBD-47E9-A5AF-4E51D0FFEA28 Q37140624-CA630672-FB9D-4191-9112-8F5BF82E83EC Q37141899-C302C9F8-6AFB-4C8A-9C55-6104122A3E8E Q37353853-2E34D69B-7E4B-4039-B7FA-8C307569403B Q37683786-2D9C298A-CE2E-44DE-BB1D-B1E24968728B Q37696776-381D5E71-FD3A-4E39-8C3A-92FECC5F8B5B Q37810200-4414BAC7-CCA6-4675-A14E-12786D8803C9 Q37861186-8CF8FCE9-87D7-44BF-96F4-020141A52C82 Q38044753-19CAB5E7-F525-4425-8464-441105C46660 Q38190857-5A0FD6BC-BFFE-44FF-A68A-58DFC6EAC398 Q38195300-30520893-1A0C-44F4-9767-8835372BBA03 Q38473846-84137966-F90D-4EBD-863E-5A61D63D3B6F Q38797683-B8B8C851-DE47-45B0-9BE3-0B12BFDBC1C9 Q39041277-20BDEEC8-EF4B-4613-83BF-32799FE2CC4D Q39061903-3BEACDEF-EBA2-455D-A360-36B6073CEDEB Q39305589-A000936B-89FB-46CB-A48B-4F35F64E4325 Q39429836-787EC694-5887-45A8-B14E-F90FDDFE52A6

P2860

Metabolism and disposition of dasatinib after oral administration to humans.

http://www.wikidata.org/entity/Q46638270

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Metabolism and disposition of dasatinib after oral administration to humans.

@en

Metabolism and disposition of dasatinib after oral administration to humans.

@nl

type

label

Metabolism and disposition of dasatinib after oral administration to humans.

@en

Metabolism and disposition of dasatinib after oral administration to humans.

@nl

prefLabel

Metabolism and disposition of dasatinib after oral administration to humans.

@en

Metabolism and disposition of dasatinib after oral administration to humans.

@nl

P1433

Q46638270-E005E1A3-857B-4888-B094-A5C0C079783D

P1476

Q46638270-A349EB0E-0C62-4298-8D7C-CD7059BD9260

P2093

Q46638270-04C354FB-9B2A-4DD7-AC2B-C880AFF3D157

Q46638270-0CF61B85-7B5E-4EDA-84BC-4E67BF5D7A27

Q46638270-1D08E959-B60D-4C33-9164-ECEBC2E8ADA7

Q46638270-4DF4D67A-F960-4AD4-9C28-6A2FFEC98D2E

Q46638270-7876FCBC-8B7D-4012-9DF9-93D7B13928D4

Q46638270-79D2B3F2-C11D-4A93-A214-72C4340423E7

Q46638270-7A32AE63-9877-4C01-8779-0FDF80CC287A

Q46638270-83D78388-C729-4930-A3C4-026DE8879031

Q46638270-881BE0B2-6623-43B4-AD19-F4AC16100E04

Q46638270-9095193C-25D1-46A7-81AB-D41C1787E905

P304

Q46638270-A41C150F-895C-441A-9E77-DACAB76B0145

P31

Q46638270-D2B44DE5-FF0B-4E9A-BEBE-21321D7D892C

P356

Q46638270-A2CFE762-A3F0-4926-9B46-526410D42608

P433

Q46638270-D6D05C91-A551-4A50-A429-5B53A854B175

P478

Q46638270-C46B7604-41D9-41A3-8A9F-A5FE9EA20A8A

P577

Q46638270-68625B27-23D2-41D0-8FB9-967CEEE0EEC5

P5875

Q46638270-E3B9D882-DDE1-4A68-9399-D1BA9E77DBB4

P698

Q46638270-B92CBBAD-9ADC-4843-BEF1-0BA23A3AEA9E

P356

P1433

Drug Metabolism and Disposition

P1476

Metabolism and disposition of dasatinib after oral administration to humans.

@en

P2093

Alban Allentoff

http://www.w3.org/2001/XMLSchema#string

Anne Blackwood-Chirchir

http://www.w3.org/2001/XMLSchema#string

Anthony Barros

http://www.w3.org/2001/XMLSchema#string

Betty McCann

http://www.w3.org/2001/XMLSchema#string

Chiyuan Wu

http://www.w3.org/2001/XMLSchema#string

Donald P Reitberg

http://www.w3.org/2001/XMLSchema#string

Donghui Cui

http://www.w3.org/2001/XMLSchema#string

Francis Y F Lee

http://www.w3.org/2001/XMLSchema#string

James A Manning

http://www.w3.org/2001/XMLSchema#string

Kan He

http://www.w3.org/2001/XMLSchema#string

P304

1357-1364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.107.018267

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5431490

http://www.w3.org/2001/XMLSchema#string

P698

18420784

http://www.w3.org/2001/XMLSchema#string